Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 27, 2025 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia's stock price declined after announcing discontinuation of NTLA-3001 program and significant workforce reduction, potentially impacting investor confidence.
The lawsuit and program discontinuation directly impact Intellia's stock, signaling potential operational challenges and reduced investor trust.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100